Active, not recruitingPhase 3NCT06246513
A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a Possible Treatment for Limb Girdle Muscular Dystrophy 2E/R4
Studying Beta-sarcoglycan-related limb-girdle muscular dystrophy R4
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sarepta Therapeutics, Inc.
- Principal Investigator
- Medical DirectorSarepta Therapeutics, Inc.
- Intervention
- SRP-9003(biological)
- Enrollment
- 17 enrolled
- Eligibility
- 4 years · All sexes
- Timeline
- 2024 – 2029
Study locations (10)
- University of California, San Diego-Altman Clinical and Translational Research Institute, La Jolla, California, United States
- Nationwide Childrens Hospital, Columbus, Ohio, United States
- The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- Children's Hospital of The King's Daughter, Norfolk, Virginia, United States
- University Hospital Leuven (UZ Leuven), Leuven, Vlaams Brabant, Belgium
- NMRC Gent (UZ Gent), Ghent, Belgium
- Universitatsklinikum Essen; Kinderklinik I, Sozialpadiatrisches Zentrum, Essen, North Rhine-Westphalia, Germany
- Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Milan, Italy
- Hospital Sant Joan de Deu, Barcelona, Spain
- Newcastle University, Newcastle upon Tyne, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06246513 on ClinicalTrials.govOther trials for Beta-sarcoglycan-related limb-girdle muscular dystrophy R4
Additional recruiting or active studies for the same condition.
See all trials for Beta-sarcoglycan-related limb-girdle muscular dystrophy R4 →